-
EASL Express丨Latest Advances in Bulevirtide Treatment for Chronic Hepatitis D
Hepatitis D virus (HDV) is a defective virus that requires the hepatitis B surface antigen (HBsAg) to replicate. Co-infection with HBV and HDV is considered the most severe form of chronic viral hepatitis, accelerating liver-related mortality and the development of hepatocellular carcinoma (HCC). At the 2024 European Association for the Study of the Liver (EASL)…
-
EASL Exclusive Interview丨Professor Jun Li: Comprehensive Research on Acute-on-Chronic Liver Failure from Pathogenesis to Clinical Treatment
Acute-on-chronic liver failure (ACLF) is a complex syndrome characterized by acute liver function deterioration based on chronic liver disease, accompanied by high mortality rates of liver and extra-hepatic organ failure. The short-term mortality rate of comprehensive internal medicine treatment ranges from 50% to 90%. Due to its high mortality and complex pathogenesis, research and treatment…
-
EASL China Voice丨Professor Shuangsuo Dang’s Team Showcases Three Achievements in Milan
From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was successfully held in Milan, Italy. During this event, the team led by Professor Shuangsuo Dang from the Department of Infectious Diseases at the Second Affiliated Hospital of Xi’an Jiaotong University presented three significant clinical and basic research findings:…
-
EASL Special Report丨Focus on the Management of Hepatitis B, Cirrhosis, and Portal Hypertension
Editor’s Note: From June 5-8, 2024, the European Association for the Study of the Liver (EASL) Annual Meeting was held in Milan, Italy. Over 7,000 hepatology experts from around the world gathered for this academic event. On the first day, the conference focused on various fields including chronic hepatitis B, cirrhosis, and portal hypertension. Hepatology…
-
EASL China Voice | Professors Jie Li, Julie Zhu, and Minghua Zheng: New Combined Non-Invasive Score Using PRO-C3 and GP73 Shows Significant Advantage in Assessing Liver Fibrosis in Chronic Hepatitis B
Liver biopsy is the “gold standard” for diagnosing liver fibrosis, but due to its high cost, invasive nature, and other disadvantages, it is not widely used. Currently, various non-invasive tests (NITs) based on serum biochemical indicators and/or imaging have been developed to evaluate liver stiffness and diagnose liver fibrosis, aiming to identify high-risk populations early…
-
EASL Highlights | EASL-EASD-EASO Jointly Release Clinical Practice Guidelines for Metabolic Associated Fatty Liver Disease
On June 7, 2024, at 5:30 PM in Milan, Italy, the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD), and the European Association for the Study of Obesity (EASO) jointly released the latest Clinical Practice Guidelines for the management of Metabolic Associated Fatty Liver Disease…
-
ASCO Hot Review | Professor Yu Chen: Safety and Efficacy of CXCR1/2 Inhibitor SX-682 in Combination with Pembrolizumab in Metastatic Melanoma Patients
As immunotherapy continues to make breakthroughs in treating malignant tumors, it has significantly improved the survival rates of melanoma patients. However, there remains an urgent need to develop new drugs and optimize immunotherapy strategies for patients resistant or intolerant to current treatments. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several…
-
ASCO China Voice | Professor Min Yan: Utidelone Combined with Bevacizumab is Safe and Effective for Treating Brain Metastases in HER2-Negative Breast
Brain metastasis from breast cancer has a high incidence, second only to lung cancer . Previous studies have shown that patients with brain metastases have poorer survival compared to those without brain metastases, with HER2-negative breast cancer brain metastasis patients having an even worse prognosis . Due to the blood-brain barrier (BBB), many drug treatments…
Connecting Medical Expertise through Media